Join Whitelist
Exclusive Whitelist to buy $PCH
The $PCH TokenPowering the Future of AI-Driven Drug Discovery
Pharmatech AI’s PCH token offers investors a direct stake in the company’s financial success through a transparent revenue-sharing model and advanced staking opportunities.
From 2028, the company projects $120 million in annual platform revenue, including $100 million from monetizing AI-driven research results (e.g., IP licenses and collaborations) and $20 million from AI-MDIP platform subscriptions. Of this, 70% ($84 million) is allocated to a Revenue Pool for advanced stakers, distributed quarterly in stablecoins based on staked token amounts and lock-up durations. Stakers can boost their rewards with loyalty multipliers (e.g., 3x for 36-month locks) and lock bonuses (up to 200% for 24 months), maximizing returns. Additionally, a fixed 5% APR staking option provides flexibility.
The buyback and burn strategy, utilizing 10% of revenues, continuously reduces the token supply, with an estimated 48 million PCH (5% of total supply) burned annually at a $0.25 token price, fostering deflationary pressure. Supported by low operational costs at the sustainable Mecklenburg-Vorpommern campus, this model ensures high margins, larger staking rewards, and a self-reinforcing value cycle. For investors, PCH represents a unique opportunity to benefit from Pharmatech AI’s growth in the $137.72 billion drug discovery market and the $41.4 billion medical cannabis market by 2030, combining financial returns with impactful innovation.
